Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
Date:5/16/2011

tin will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its third quarter of fiscal year 2011 financial results and plans for its programs under development.  Individuals interested in listening to the conference call live can dial 1-866-316-1363 (domestic) or 1-913-312-0861 (international), Pass code 2950108. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), Pass code 2950108.  The webcast and telephone replay will be available through May 23, 2011.  

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Ex
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... N.J., Oct. 8 Managed Health Care,Associates, Inc. ... that it plans to open the 2008 MHA ... Secretary, Health and Human Services,(2001-2005), former four-term Governor ... Independent Chairman, Deloitte,Center for Health Solutions. Marking the ...
... announced today that it has entered into a ... producer of infant,formula products including the Similac(R) Advance(R) ... and ARA supplier for all of its,infant formula ... with,Abbott having the right to terminate the arrangement ...
... patients to benefit from rapid, long-lasting symptom control with ... ... fumarate -, NAPA, Calif., Oct. 8 Dey, L.P., ... the launch of Perforomist(TM),(formoterol fumarate) Inhalation Solution, which will be ...
Cached Biology Technology:MHA Announces: Tommy Thompson to be Keynote Speaker at The MHA 5th Annual Business Summit 2Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6
(Date:4/23/2014)... the first cause of dementia and affects some 400,000 ... yet been found. One of the reasons for this ... which cause alterations in nerve transmissions and the loss ... Researchers from the Institute of Neuroscience at the Universitat ... in memory consolidation and were able to develop a ...
(Date:4/23/2014)... April 23, 2014 A biomedical engineer at the ... innovative technology to make blood transfusions safer. His work ... National Institutes of Health (NIH). , Blood transfusions ... of modern medicine,s absolute necessities. Without them, for instance, ... transfusions are perfect, however. There,s strong evidence that transfusions ...
(Date:4/23/2014)... used to read quickly. It involves visual searching ... and/ or sentences. Similarly to humans, biological systems ... genetic information. Genes that need to be read ... encoding message, the easier it will be to ... de Cincia (IGC, Portugal) and Centre for Molecular ...
Breaking Biology News(10 mins):Loss of memory in Alzheimer's mice models reversed through gene therapy 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Cell division speed influences gene architecture 2
... the oil industry will need more refined tools for discoveries ... say. One such tool is a new sediment curve ... the Paleozoic Era 542 to 251 million years ago, scientists ... . The sediment curve covers the entire Paleozoic Era. ...
... his dog to salivate in anticipation of food when ... certain behaviors when enticed with different smells. Researchers at ... of Hong Kong and the National Institute of Standards ... the interval between the signal, or odor, and the ...
... Exposure to Bisphenol A (BPA), phthalates and flame retardants ... humans and laboratory animals. A special section in the ... Plastic World" provides critical new research on environmental contaminants ... products contain "endocrine disrupting chemicals" that can block the ...
Cached Biology News:Paleozoic 'sediment curve' provides new tool for tracking sea-floor sediment movements 2Moths with a nose for learning 26 environmental research studies reveal critical health risks from plastic 2
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
... is a tetramethylrhodamine-conjugated jetSI-ENDO (excitation ... 580 nm), the powerful siRNA ... used to determine the transfection ... delivery and trafficking of siRNAs. ...
... in a Morris Water Maze. Tracks up ... sequence of trials.The Spatial Behavior line is a ... camera, frame grabber, and feature extraction software and ... up to 6 moving animals. Software automatically ...
... GEA Diessel fermentation systems for cultivation of ... provided manufacturers of bio-pharmaceutical products maximum performance ... For microbial and cell fermentation 10 L ... dead-leg areas ,*Fully automated control system ...
Biology Products: